Logo

Press Releases


November 18, 2020
Pionyr Immunotherapeutics Initiates Phase 1 Clinical Study of PY314

June 23, 2020
Gilead Sciences Secures Exclusive Option to Acquire Pionyr Immunotherapeutics

August 27, 2019
Pionyr Immunotherapeutics Announces Key Leadership Team Addition and Clinical Candidates Targeting Tumor-Associated Macrophages

July 10, 2018
Pionyr Immunotherapeutics and ProBioGen Initiate a Second Immuno-Oncology Contract Development and Manufacturing Project

December 13, 2017
Pionyr Immunotherapeutics Completes $62 million Series B Financing to Advance Antibody-Based Therapeutics Targeting the Tumor Microenvironment

January 4, 2017
Pionyr Immunotherapeutics Closes Financing with Focus on Developing Antibody-based Immuno-oncology Therapeutics

  • About
    • Overview
    • Pionyr Path
    • Leadership
    • Board of Directors
    • Scientific Advisors Board
    • Investors & Partners
  • Pipeline
    • Pipeline
    • Myeloid Tuning
    • Programs
    • PY314
    • PY159
    • Posters & Publications
  • News
    • Press Releases
    • Events
    • In The News
  • Careers
    • Life as a Pionyr
    • Our Values
    • Open Positions
    • Culture
    • Benefits
  • LinkedIn
  • Twitter
  • Home
  • About
    • Overview
    • Pionyr Path
    • Leadership
    • Board of Directors
    • Scientific Advisors Board
    • Investors & Partners
  • Pipeline
    • Pipeline
    • Myeloid Tuning
    • Programs
    • PY314
    • PY159
    • Posters & Publications
  • News
    • Press Releases
    • Events
    • In The News
  • Careers
    • Life as a Pionyr
    • Our Values
    • Open Positions
    • Culture
    • Benefits
  • LinkedIn
  • Twitter

logo

© 2021 Pionyr Immunotherapeutics All rights reservedWebsite Design: Hane Chow, Inc.
  • LinkedIn
  • Twitter